|
Simon Campbell, Ph.D, FRS, received his PhD from the University of Birmingham in 1965 followed by postdoctoral appointments in Chile and Stanford. From 1969 to 1972 he was Visiting Professor at the Universidade do Sao Paulo in Brasil and he joined Pfizer Central Research, Sandwich UK in 1972. Dr. Campbell retired in 1998 as Senior Vice President for Worldwide Discovery and Medicinals R&D Europe. He has co-authored over 110 publications and patents, and was a key member of the research teams that discovered CarduraTM, NorvascTM, and Viagra.TM
Dr. Campbell's contributions have been recognised by the Royal Society of Chemistry Award for Medicinal Chemistry (1989), the Herschberg Award from the American Chemical Society, the Industrial Research Institute (US) Achievement Award (1997), and the CIA Individual Achievement Award (2006). He was elected Fellow of the Royal Society (1999), Fellow of the Academy of Medical Sciences (2002) and was awarded a CBE in the Queen's Birthday Honours List (2006).
Currently, Dr. Campbell is a member of the SABs of Astex (Cambridge), Chroma (Oxford), DanioLabs (Cambridge) Inpharmatica (London), Merlion (Singapore) S*Bio (Singapore), Sunesis (San Francisco) and Synomix (San Diego). He acts as consultant to Abingworth Management (London) Almirall (Barcelona) and Jerini (Berlin). He is immediate past President of the Royal Society of Chemistry, serves on the Council of the University of Kent and the Advisory Council for Save British Science Dr. Campbell joined the Senomyx Scientific Advisory Board in September 2005. | 